NICE opens door to Roche, AZ cancer drugs

The U.K.'s cost-effectiveness watchdog has given the final nod to a trio of cancer drugs--Roche's Xeloda and MabThera, and AstraZeneca's Iressa--which means the NHS must provide funding and resources for them in the next three months. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.